Navigation Links
Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results

NEW BRUNSWICK, N.J., Feb. 15 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT) today reported financial results for the three months ended December 31, 2007.

Net loss for the three month period ended December 31, 2007 was $1.3 million, or $0.07 per share, compared with a net loss of $1.1 million, or $0.07 per share, for the three month period ended December 31, 2006. This increase in net loss was primarily the result of a decrease in revenue and an increase in expenses associated with the outstanding convertible notes that were issued during the current fiscal year, which was partially offset by a decrease in operating expenses.

Quarterly and Recent Highlights

-- Senesco closed on an additional gross amount of $5.5 million of its

previously announced private placements with YA Global Investments, LP

("YA Global") and Stanford Venture Capital Holdings, Inc. ("Stanford").

Through January 31, 2008, Senesco has now closed on an aggregate of

$7 million of the $10 million private placements of secured convertible

debentures and warrants and has met the three triggering milestones

necessary in order to fix the conversion price of the convertible notes

issued to YA Global and Stanford at $0.90 per share of common stock.

-- Senesco selected Cato Research, a leading contract research

organization ("CRO"), to assist the Company with its goal of initiating

a clinical trial.

-- Senesco initiated and announced the results of certain preclinical

animal studies focused on multiple myeloma. In the studies, SCID

(severe combined immunodeficiency) mice were injected subcutaneously

with human multiple myeloma cancer cells to form myeloma tumors in

their flanks. Treated mice were injected intratumorally with Factor 5A

therapy encapsulated in nanoparticles, while control mice received a

nanoparticle without the Factor 5A therapy. One of the dosing regimens

showed evidence of significant tumor regression relative to the

untreated control mice, while the other showed a diminished rate of

tumor growth along with some regression.

"As our recent accomplishments indicate, we continue to execute on our strategy," said Bruce Galton, President and CEO of Senesco. We believe we have advanced our human health preclinical research program via the selection of a CRO and the successful completion of certain in-vivo preclinical studies in multiple myeloma. Our objectives for the remainder of the year are to continue to evaluate dosing regimens and encapsulation vehicles in preclinical multiple myeloma cancer models, to identify contract manufacturing centers to produce cGMP materials, to plan and carry out the necessary toxicology studies, and to work with our CRO to begin preparation of an Investigational New Drug Application."

-- Revenue of $6,250 for the three month period ended December 31, 2007

consisted of the amortized portion of previous milestone payments

received in connection with certain license agreements. During the

three-month period ended December 31, 2006, revenue of $181,250

consisted of initial fees, milestone payments and the amortized portion

of previous milestone payments received in connection with certain

development and license agreements.

-- Research and development expenses during the three month period ended

December 31, 2007 were $392,254, compared with $239,395 during the

three month period ended December 31, 2006. This increase resulted

from an increase in the budget for the banana field trials, an

unfavorable exchange rate variance in connection with our research

agreement at the University of Waterloo and the initiation of certain

human health-related research projects that were not in progress during

the three month period ended December 31, 2006. The Company expects

research and development expenses to continue to increase as it expands

its research activities, particularly in the area of human health.

-- General and administrative expenses were $586,000 for the three month

period ended December 31, 2007, compared with $1.1 million during the

three month period ended December 31, 2006. This decrease was

primarily due to lower stock-based compensation expense, which was

partially offset by an increase in depreciation and amortization.

-- At December 31, 2007, Senesco had cash, cash equivalents and

investments of $5,135,644. With the remaining potential gross proceeds

of our previously announced $10 million financing, Senesco should be

able to operate according to the Company's current business plan for

the next 21 months. As previously disclosed, the Company has closed on

$7 million of the $10 million financing. The receipt of the remaining

$3 million of proceeds is dependent upon entering into certain supply

agreements with third party manufacturers. If Senesco does not meet

all or some of the foregoing funding milestones, then the current

$5.1 million is only sufficient for the next 13 months.

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene- regulating platform technology to enhance its partners' products.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, the Company's ability to meet its funding milestones under its financing transaction, the Company's ability to comply with the continued listing standards of the AMEX, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.





For the For the

Three Months Ended Three Months Ended

December 31, December 31,

2007 2006

Revenue $6,250 $181,250

Operating Expenses:

General and administrative 585,851 1,103,594

Research and development 392,254 239,395

Total Operating Expenses 978,105 1,342,989

Loss From Operations (971,855) (1,161,739)

Sale of state income tax loss, net -- --

Other noncash income -- --

Interest income, net 25,227 26,102

Amortization of debt discount

and financing costs (283,207) --

Interest expense on

convertible notes (64,836) --

Net Loss $(1,294,671) $(1,135,637)

Basic and Diluted

Net Loss Per Common Share $(0.07) $(0.07)

Basic and Diluted

Weighted Average Number

of Common Shares Outstanding 17,474,870 17,257,791


Inception on

For the For the July 1, 1998

Six Months Ended Six Months Ended through

December 31, December 31, December 31, 2007

2007 2006

Revenue $377,500 $262,500 $1,095,833

Operating Expenses:

General and

administrative 974,910 1,486,879 20,409,103

Research and

development 745,149 548,743 8,938,318

Total Operating

Expenses 1,720,059 2,035,622 29,347,421

Loss From

Operations (1,342,559) (1,773,122) (28,251,588)

Sale of state

income tax loss, net -- -- 586,442

Other noncash income -- -- 321,259

Interest income, net 32,106 37,020 411,894

Amortization of debt

discount and

financing costs (298,428) -- (298,428)

Interest expense

on convertible notes (67,836) -- (67,836)

Net Loss $(1,676,717) $(1,736,102) $(27,298,257)

Basic and Diluted

Net Loss Per

Common Share $(0.10) $(0.11)

Basic and Diluted

Weighted Average

Number of Common

Shares Outstanding 17,474,282 16,369,220




December 31, June 30,

2007 2007




Cash and cash equivalents $5,135,644 $408,061

Short-term investments 500,000 250,000

Prepaid expenses and other current assets 52,959 104,526

Total Current Assets 5,688,603 762,587

Property and equipment, net 5,444 7,526

Intangibles, net 2,896,958 2,544,447

Deferred financing costs 748,949 --

Security deposit 7,187 7,187

TOTAL ASSETS $9,347,141 $3,321,747



Accounts payable $552,026 $109,258

Accrued expenses 368,570 377,359

Deferred revenue 4,167 16,667

Total Current Liabilities 924,763 503,284

Convertible note, net of discount 257,560 --

Grant payable 99,728 99,728

Other liability 26,129 29,196

TOTAL LIABILITIES 1,308,180 632,208


Preferred stock, $0.01 par value;

authorized 5,000,000 shares, no shares issued -- --

Common stock, $0.01 par value;

authorized 100,000,000 shares,

issued and outstanding

17,581,852 and 17,473,694, respectively 175,819 174,737

Capital in excess of par 35,161,399 28,136,342

Deficit accumulated during

the development stage (27,298,257) (25,621,540)

TOTAL STOCKHOLDERS' EQUITY 8,038,961 2,689,539


Company Contact: Investor Relations Contact:

Senesco Technologies, Inc. FD

Joel Brooks Brian Ritchie

Chief Financial Officer (212) 850-5600

(732) 296-8400

SOURCE Senesco Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
2. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
7. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
8. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
9. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
10. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
11. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
Post Your Comments:
(Date:10/7/2017)... ... October 06, 2017 , ... ... launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available ... bioinformatics software to perform Hi-C metagenome deconvolution using their own facilities, supplementing ...
(Date:10/6/2017)... ... October 06, 2017 , ... The HealthTech ... technology sector at their fourth annual Conference where founders, investors, innovative practitioners and ... the ELEVATE pitch competition showcasing early stage digital health and med tech companies. ...
(Date:10/5/2017)... ... October 05, 2017 , ... LabRoots , the leading ... around the world, is giving back to cancer research with a month-long promotion supporting ... Now through October 31, shoppers can use promo code PinkRibbon to get 10 percent ...
(Date:10/5/2017)... , ... October 05, 2017 , ... ... develop new applications of its Nanobind DNA/RNA extraction technology . Nanobind is ... silica on the surface and that can be used for a wide variety ...
Breaking Biology Technology:
(Date:8/15/2017)... 15 2017   ivWatch LLC , a medical device company ... today announced receipt of its ISO 13485 Certification, the global standard ... Organization for Standardization (ISO®). ... Model 400 Continuous Monitoring device for the early detection of IV ... "This is an important milestone for ...
(Date:6/14/2017)... , June 15, 2017  IBM (NYSE: IBM ) ... international tech event dedicated to developing collaboration between startups and ... on June 15-17. During the event, nine startups will showcase ... value in various industries. France ... the international market, with a 30 percent increase in the ...
(Date:5/6/2017)... 5, 2017 RAM Group , ... new breakthrough in biometric authentication based on a ... properties to perform biometric authentication. These new sensors are ... created by Ram Group and its partners. This sensor ... supply chains and security. Ram Group is a ...
Breaking Biology News(10 mins):